{"name":"NOVARTIS PHARMS CORP","slug":"novartis-pharms-corp","ticker":"","exchange":"","domain":"novartispharms.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1369000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Ilaris","genericName":"CANAKINUMAB","slug":"canakinumab","revenue":1369000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2009-01-01","label":"Ilaris first approved","drug":"Ilaris","drugSlug":"canakinumab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-04-19","label":"ADAKVEO Phase 3 readout (Sickle Cell Disease)","drug":"ADAKVEO","drugSlug":"crizanlizumab-tmca","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":1369000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ilaris","genericName":"CANAKINUMAB","slug":"canakinumab","indication":"Articular gout","status":"marketed","revenue":1369000000}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ADAKVEO","genericName":"CRIZANLIZUMAB-TMCA","slug":"crizanlizumab-tmca","indication":"Vaso-occlusive crisis in sickle cell disease","status":"marketed"}]}],"pipeline":[{"name":"Ilaris","genericName":"CANAKINUMAB","slug":"canakinumab","phase":"marketed","mechanism":"Interleukin-1 beta","indications":["Articular gout","Cryopyrin associated periodic syndrome","Deficiency of mevalonate kinase","Familial Mediterranean fever","Systemic onset juvenile chronic arthritis"],"catalyst":""},{"name":"ADAKVEO","genericName":"CRIZANLIZUMAB-TMCA","slug":"crizanlizumab-tmca","phase":"marketed","mechanism":"P-selectin","indications":["Vaso-occlusive crisis in sickle cell disease"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}